Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis-Reference-Cited by-同舟云学术

Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis

Published:2019-04 Issue: Volume:136 Page:64-69
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Marchetti Claudia^ORCID,De Felice Francesca^ORCID,Perniola Giorgia,Palaia Innocenza,Musella Angela,Di Donato Violante,Cascialli Gianluca,Muzii Ludovico,Tombolini Vincenzo,Benedetti Panici Pierluigi

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer;Alberts;N. Engl. J. Med.,1996

2. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N. Engl. J. Med.,2006

3. Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications;Benedetti-Panici;Int. J. Gynecol Cancer,2012

4. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer;Chan;N. Engl. J. Med.,2016

5. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events. Available at: http://ctep.cancer.gov.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of intraperitoneal chemotherapy for advanced ovarian cancer – The experience of a tertiary referral centre;Australian and New Zealand Journal of Obstetrics and Gynaecology;2023-11-22

2. Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis;PLOS ONE;2023-11-17

3. Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and management;Frontiers in Immunology;2023-02-03

4. Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies;Drugs;2023-01-12

5. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis;ESMO Open;2022-10